Unknown

Dataset Information

0

Measuring the biological effect of presurgical metformin treatment in endometrial cancer.


ABSTRACT: Preclinical studies in endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR inhibition. We tested the hypothesis that short-term presurgical metformin reduces cellular proliferation in atypical endometrial hyperplasia (AEH) and endometrioid EC, and assessed the feasibility of using phosphorylated PI3K-AKT-mTOR proteins as tissue end points.Women with AEH or EC received metformin 850 mg twice a day or no drug in the presurgical window between diagnosis and hysterectomy. Before and after the window, tissue samples were obtained; serum markers of insulin resistance (e.g. homeostasis model of assessment of insulin resistance index) were determined; and anthropometrics measured (e.g. BMI). Cell proliferation (Ki-67) and PI3K-AKT-mTOR phosphostatus were assessed by immunohistochemistry and scored blinded to treatment.Twenty-eight metformin-treated and 12 untreated patients, well matched for age and BMI, completed the study. Metformin treatment (median 20 days, range 7-34) was associated with a 17.2% reduction in tumour Ki-67 (95% CI -27.4, -7.0, P=0.002), in a dose-dependent manner. Tumour PI3K-AKT-mTOR protein phosphostatus varied but the effects were not significant after adjusting for changes in controls.Short-term metformin was associated with reduced Ki-67 expression in EC. Changes in tumour PI3K-AKT-mTOR protein phosphostatus were seen in both groups. Future studies should address the variability attributed to different sampling techniques including devascularisation of the uterus at hysterectomy.

SUBMITTER: Sivalingam VN 

PROVIDER: S-EPMC4742583 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Measuring the biological effect of presurgical metformin treatment in endometrial cancer.

Sivalingam V N VN   Kitson S S   McVey R R   Roberts C C   Pemberton P P   Gilmour K K   Ali S S   Renehan A G AG   Kitchener H C HC   Crosbie E J EJ  

British journal of cancer 20160121 3


<h4>Background</h4>Preclinical studies in endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR inhibition. We tested the hypothesis that short-term presurgical metformin reduces cellular proliferation in atypical endometrial hyperplasia (AEH) and endometrioid EC, and assessed the feasibility of using phosphorylated PI3K-AKT-mTOR proteins as tissue end points.<h4>Methods</h4>Women with AEH or EC received metformin 850 mg twice a day or no drug in the presurg  ...[more]

Similar Datasets

| S-EPMC3844911 | biostudies-literature
| S-EPMC4435671 | biostudies-literature
| S-EPMC6779615 | biostudies-literature
| S-EPMC6485333 | biostudies-literature
| S-EPMC7943011 | biostudies-literature
| S-EPMC5256996 | biostudies-literature
| S-EPMC6834476 | biostudies-literature
| S-EPMC7077930 | biostudies-literature
| S-EPMC5907461 | biostudies-literature
| S-EPMC6507480 | biostudies-literature